Takeda's Mezagitamab Shows Positive Results for Primary …
2024年3月13日 · Mezagitamab is a fully human immunoglobulin IgG1 monoclonal antibody (mAb) with high affinity for CD38 expressing cells (including plasmablasts, plasma cells, natural killer cells) resulting in their depletion.
Takeda's anti-CD38 antibody boosts platelet count in phase 2
2024年6月24日 · Takeda may have pruned back the potential indications for mezagitamab, but the latest raft of phase 2 data suggests the anti-CD38 antibody could still “transform treatment” of primary immune...
Takeda’s mezagitamab shows promise in immune …
2024年6月27日 · Takeda has announced promising mid-stage results for mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP).
Phase 1b study of the anti-CD38 antibody mezagitamab in …
2024年12月1日 · This phase 1b trial aimed to determine the safety, tolerability, and preliminary efficacy of mezagitamab, a subcutaneously administered anti-CD38 monoclonal antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
ISTH 2024 – Takeda's marker for Genmab and Sanofi
2024年6月24日 · If the rare immune-mediated bleeding disorder immune thrombocytopenia (ITP) represents a new use for anti-CD38 therapy then Takeda’s mezagitamab just gave Johnson & Johnson/Genmab’s Darzalex and Sanofi’s Sarclisa something to shoot for.
Mezagitamab Achieves Platelet Response, Favorable Safety in
2024年6月25日 · Mezagitamab is a fully-human immunoglobulin IgG1 monoclonal antibody with a high affinity for CD83-expressing cells. 1 The therapy is designed to provide rapid, sustained improvement in platelet response and restore platelet counts to functional levels.
Mezagitamab in systemic lupus erythematosus: clinical and
2024年3月7日 · Mezagitamab had a favourable safety profile in patients with moderate to severe SLE and elicited a pharmacodynamic effect consistent with CD38+ cell depletion. These findings reveal novel insights into the drug's mechanism of action and support the continued investigation of mezagitamab in autoimmun …
Mezagitamab in systemic lupus erythematosus: clinical and …
2024年3月6日 · Mezagitamab, an anti-CD38 antibody, has a favourable safety profile in patients with moderate to severe SLE. Mezagitamab induces broad immune landscape changes consistent with CD38+ cell depletion and reduction in type 1 interferon signalling. Mezagitamab may have utility in various autoimmune diseases driven by CD38-expressing cells.
Takeda Unveils Promising Phase 2b Results for Mezagitamab in …
2024年6月22日 · The Phase 2b trial results demonstrated that mezagitamab treatment improved platelet response compared to placebo, across all three dose levels of mezagitamab tested.
Mezagitamab by Takeda Pharmaceutical for Systemic Lupus …
2024年6月18日 · Mezagitamab (TAK-079) is under development for the treatment of primary immune thrombocytopenia, myasthenia gravis, primary IgA nephropathy, systemic lupus erythematosus, relapsed/refractory multiple myeloma and newly diagnosed multiple myeloma.
- 一些您可能无法访问的结果已被隐去。显示无法访问的结果